Search - tctmd.com

Displaying 241 - 260 of 765

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2020

Caitlin E. Cox

August 28, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Daily News

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Michael O'Riordan

July 14, 2020

News Daily News

Short DAPT Reduces Bleeding With No Increase in MACE: Meta-analysis

Yael L. Maxwell

June 30, 2020

News Conference News TVT 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Yael L. Maxwell

June 26, 2020

News Daily News

Most Stable Angina Patients Not Taking First-line Meds

Shelley Wood

June 18, 2020

News Daily News

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

L.A. McKeown

June 17, 2020

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Daily News

US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable

Shelley Wood

May 29, 2020

News Daily News

More Missing MIs, Late Complications Blamed on COVID-19 in Italy and California

Shelley Wood

May 22, 2020

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

Caitlin E. Cox

May 15, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Todd Neale

March 28, 2020

Advertisement

TCTMD’s Top 10 Most Popular Stories for August 2020

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Short DAPT Reduces Bleeding With No Increase in MACE: Meta-analysis

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Most Stable Angina Patients Not Taking First-line Meds

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

US Prescriptions During COVID-19: Hydroxychloroquine Soars, CVD Drugs Stable

More Missing MIs, Late Complications Blamed on COVID-19 in Italy and California

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content